EDSA Stock Overview
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Edesa Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.38 |
| 52 Week High | US$8.61 |
| 52 Week Low | US$2.46 |
| Beta | 0.92 |
| 1 Month Change | 2.34% |
| 3 Month Change | -6.79% |
| 1 Year Change | -45.11% |
| 3 Year Change | -90.02% |
| 5 Year Change | n/a |
| Change since IPO | -87.97% |
Recent News & Updates
Recent updates
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely
Aug 04
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate
Mar 10Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%
Sep 30Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Sep 23Edesa says mid-stage trial for anti-allergic cream reached full enrollment
Sep 07Edesa Biotech GAAP EPS of -$0.37 beats by $0.06
Aug 12Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth
May 16Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD
Apr 18Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Dec 08Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
Sep 22Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Aug 27Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study
Jun 18Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?
Apr 13Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)
Feb 19Edesa Biotech receives C$14M for COVID-19 study
Feb 02Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Dec 08
Edesa Biotech EPS misses by $0.04, beats on revenue
Dec 07Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment
Nov 03Shareholder Returns
| EDSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | -2.5% | -3.2% |
| 1Y | -45.1% | -3.7% | 19.3% |
Return vs Industry: EDSA underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: EDSA underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| EDSA volatility | |
|---|---|
| EDSA Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EDSA's share price has been volatile over the past 3 months.
Volatility Over Time: EDSA's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 16 | Par Nijhawan | www.edesabiotech.com |
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.
Edesa Biotech, Inc. Fundamentals Summary
| EDSA fundamental statistics | |
|---|---|
| Market cap | US$14.09m |
| Earnings (TTM) | -US$7.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs EDSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.72m |
| Earnings | -US$7.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EDSA perform over the long term?
See historical performance and comparison